Gastric CancerHepatocellular CarcinomaNon-Small-Cell Lung CancerColon Rectal Cancer
Investigational drug(s) / intervention(s)
DC vaccine subcutaneous administration
DC vaccine subcutaneous administration: subcutaneous administration
Study summary
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.
Eligibility
Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria:
* Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation
* Anticipated life time \> 3month
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
* Adequate organ functions
Exclusion Criteria:
* Any evidence of tumor metastasis or co-existing malignant disease
* Tumor emergency
* Abnormal coagulation condition
* Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
* Concomitant tumors
* Immunological co-morbidities
Primary outcome measure(s)
Disease-free Survival (DFS) — Up to 5 years Defined as the time from the surgery to the first documented disease recurrence or death (by any cause), whichever occurs first
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.